TABLE 4.

Effects of Torcetrapib on Precursors of Bile Acid and Cholesterol Synthesis and Fecal Bile Acid and Neutral Sterol Content

Parameter	Atorvastatin+Torcetrapib	Torcetrapib
	120 mg QD n=9	120 mg QD n=10	120 mg BID n=6
Serum 7α-hydroxy-4-cholesten-3-one, ng/mL
Placebo	23±20	38±29	29±18
Torcetrapib	22±13	36±27	38±22
% change	16±66	17±52	35±49
Serum lathosterol, μg/mL
Placebo	0.6±0.3†	2.0±0.8	1.7±0.5
Torcetrapib	0.5±0.2†	2.4±0.9	2.3±1.0
% change	−18±28¶	16±20	32±43
Fecal bile acids, mg/mg plant sterols
Placebo	1.4±0.4	2.4±1.5	1.9±0.7
Torcetrapib	1.2±0.4*||	2.2±1.2	2.2±1.1
% change	−16±20	4±50	13±46
Fecal neutral sterols, mg/mg plant sterols
Placebo	1.9±0.7‡	3.3±1.0	2.9±0.5
Torcetrapib	1.7±0.4†	3.3±0.6	2.9±1.0
% change	−8±22	5±28	−1±32

^*P<0.04 for comparison with placebo phase;

^†P<0.0001;

^‡P<0.01;

^¶P<0.02;

^||P<0.05 for comparison with 120 mg nonatorvastatin torcetrapib QD cohort.